Browse the evidence

Several emerging oral agents have demonstrated promising efficacy, achieving weight loss of ≥10% in clinical trials.

Practitioners may consider these oral agents as effective options for weight management.

Incretin-based therapy reduced all-cause mortality by 18%.

Incretin-based therapies may improve survival rates in overweight or obese individuals.

Obesity leads to inflammation and altered hormone production that can promote cancer development.

Understanding the hormonal and inflammatory changes in obesity can help in developing targeted interventions for cancer prevention.

Semaglutide was associated with a reduction in heavy drinking days by -41.1 percentage points from baseline compared to placebo, which had a reduction of -26.4 percentage points.

Semaglutide may be a viable treatment option for reducing heavy drinking in patients with alcohol use disorder and obesity.

Semaglutide improved heart failure symptoms and physical limitations in participants with obesity-related HFpEF.

Practitioners can consider semaglutide as an effective treatment for improving symptoms in patients with obesity-related HFpEF.

Randomized trials with liraglutide and semaglutide have shown reductions in major adverse cardiovascular events.

These medications may be beneficial for patients at high risk of cardiovascular events.

Continuing GLP-1 or GIP agonists before upper endoscopy increases the risk of clinically significant residual gastric volume (RGV).

Practitioners should consider holding GLP-1 or GIP agonists prior to upper endoscopy to reduce the risk of RGV.

Holding one dose of GLP-1 or GIP agonists significantly reduces the risk of clinically significant RGV.

Holding the medication prior to the procedure is advisable to minimize RGV risk.

Clear liquids the day prior to the procedure may mitigate the risk of clinically significant RGV regardless of GLP-1/GIP use.

Encouraging clear liquids before procedures may help reduce RGV risk.

Semaglutide improved glycemic control, with HbA1c decreasing by 0.4 ± 0.6%.

Semaglutide may be a beneficial treatment for improving glycemic control in patients with type 1 diabetes.

1 kg/m² lower BMI via the GIP/GIPR score is associated with 29% lower risk of major adverse cardiovascular events (MACE).

Targeting GIP receptor pathways may significantly reduce cardiovascular event risk.

1 kg/m² lower BMI via the GIP/GIPR score is associated with 43% lower risk of heart failure.

Targeting GIP receptor pathways may significantly reduce heart failure risk.

Menopause is associated with weight gain and a predisposition to obesity in women.

Practitioners should be aware of the increased risk of weight gain in menopausal women.

Women begin to lose lean mass during menopause, leading to an increase in fat mass.

Practitioners should monitor body composition changes in menopausal women.

Targeted antiobesity medications (AOM) have demonstrated significant weight loss and improved quality of life in patients with specific genetic obesity disorders.

Practitioners should consider targeted AOMs for patients with genetic obesity disorders to improve weight management and quality of life.

Nontargeted AOMs can achieve similar benefits in patients with specific genetic obesity disorders compared to common multifactorial obesity.

Practitioners may consider nontargeted AOMs as an alternative for managing obesity in patients with genetic disorders.

GLP-1RA-induced weight loss would lead to a marked decrease in cancer cases over 10 years in adults.

Implementing GLP-1RA treatments could significantly reduce cancer incidence in obese populations.

If GLP-1RAs were made available for all people with obesity and 50% moved into a lower BMI category, there would be a simulated reduction in cumulative cancer cases of 21,443.

Wider access to GLP-1RAs could lead to significant reductions in cancer cases among obese individuals.

GLP-1 receptor agonists promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.

GLP-1 receptor agonists can be considered for managing type 2 diabetes and obesity in clinical practice.

GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes.

Consider GLP-1 receptor agonists for patients at high risk of cardiovascular issues or renal failure.

Tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.

Tirzepatide may be a promising treatment option for patients with MASH, potentially improving liver health.

More patients in the tirzepatide group achieved a 1-stage or greater fibrosis improvement without worsening of MASH compared to placebo.

Tirzepatide may help improve liver fibrosis in patients with MASH.

Tirzepatide has been approved for the treatment of adults with type 2 diabetes who are overweight/obese or have weight-related comorbidities.

Tirzepatide is a viable treatment option for managing type 2 diabetes in specific patient populations.

GLP-1 receptor agonists have demonstrated cardioprotection in patients with type 2 diabetes and heart failure.

Incorporating GLP-1RAs into treatment plans may improve cardiovascular outcomes in diabetic patients.